Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 20;40(12):1356-1384.
doi: 10.1200/JCO.21.02528. Epub 2021 Dec 22.

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Megan E Daly  1 , Navneet Singh  2 , Nofisat Ismaila  3 , Mara B Antonoff  4 , Douglas A Arenberg  5 , Jeffrey Bradley  6 , Elizabeth David  7 , Frank Detterbeck  8 , Martin Früh  9   10 , Matthew A Gubens  11 , Amy C Moore  12 , Sukhmani K Padda  13 , Jyoti D Patel  14 , Tanyanika Phillips  15 , Angel Qin  5 , Clifford Robinson  16 , Charles B Simone 2nd  17
Affiliations
Review

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Megan E Daly et al. J Clin Oncol. .

Abstract

Purpose: To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC).

Methods: An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncology, research methodology, and advocacy experts was convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.

Results: The literature search identified 127 relevant studies to inform the evidence base for this guideline.

Recommendations: Evidence-based recommendations were developed to address evaluation and staging workup of patients with suspected stage III NSCLC, surgical management, neoadjuvant and adjuvant approaches, and management of patients with unresectable stage III NSCLC.Additional information is available at www.asco.org/thoracic-cancer-guidelines.

PubMed Disclaimer

Conflict of interest statement

Megan E. DalyEmployment: University of CaliforniaLeadership: International Journal of Radiation Oncology Biology Physics, Practical Radiation OncologyConsulting or Advisory Role: Boston Scientific, Triptych Health PartnersResearch Funding: EMD Serono, Genentech (Inst), Merck (Inst)Travel, Accommodations, Expenses: Boston ScientificOther Relationship: TeleSecurity Sciences/Imatex Nofisat IsmailaEmployment: GlaxoSmithKline (I)Stock and Other Ownership Interests: GlaxoSmithKline (I) Douglas A. ArenbergUncompensated Relationships: American College of Chest Physicians, CHEST JournalOpen Payments Link: https://openpaymentsdata.cms.gov/physician/47744/summary Jeffrey BradleyHonoraria: AstraZeneca/MedImmune, Mevion Medical SystemsConsulting or Advisory Role: Varian Medical Systems, Genentech Elizabeth DavidHonoraria: AstraZenecaTravel, Accommodations, Expenses: Intuitive Surgical Martin FrühConsulting or Advisory Role: BMS (Inst), AstraZeneca (Inst), MSD (Inst), Takeda (Inst), Roche (Inst), Lilly (Inst), Roche (Inst)Speakers' Bureau: Pfizer (Inst)Research Funding: BMS (Inst), AstraZeneca (Inst), AstraZeneca (Inst) Matthew A. GubensConsulting or Advisory Role: Bristol Myers Squibb, AstraZeneca, Sanofi/Regeneron, ITeos TherapeuticsResearch Funding: Celgene (Inst), Merck (Inst), Novartis (Inst), Genentech/Roche (Inst), OncoMed (Inst), Trizell (Inst), Amgen, Johnson & Johnson/Janssen Amy C. MooreConsulting or Advisory Role: Guardant Health, Merck (Inst) Sukhmani K. PaddaHonoraria: CME Solutions, Janssen, MECC Global Meetings (CME), Nanobiotix, Physician Education Resource (CME), Jazz PharmaceuticalsConsulting or Advisory Role: AstraZeneca, G1 Therapeutics, Blueprint Medicines, AstraZeneca (Steering Committee), Genentech, Jazz Pharmaceuticals, Mirati Therapeutics, Janssen Oncology, GenzymeResearch Funding: EpicentRx (Inst), Bayer (Inst), Boehringer Ingelheim (Inst)Other Relationship: OncLive/MJH Life Sciences Jyoti D. PatelConsulting or Advisory Role: AbbVie, AstraZeneca, Takeda Science FoundationResearch Funding: Bristol Myers Squibb (Inst) Tanyanika PhillipsTravel, Accommodations, Expenses: City of Hope Angel QinResearch Funding: Takeda (Inst), Clovis Oncology (Inst), Merck Sharp & Dohme (Inst) Clifford RobinsonLeadership: RadialogicaStock and Other Ownership Interests: RadialogicaConsulting or Advisory Role: Varian Medical Systems, AstraZeneca, EMD Serono, Quantitative Radiology SolutionsResearch Funding: Varian Medical Systems (Inst), Merck (Inst)Patents, Royalties, Other Intellectual Property: Noninvasive imaging and treatment system for cardiac arrhythmias WO 2017078757 A1, US Provisional Application No. 62/598,162 Entitled System and Method for Determining Segments for Ablation Charles B. Simone IIHonoraria: Varian Medical SystemsNo other potential conflicts of interest were reported.

Comment in

LinkOut - more resources